Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas

A Systematic Review

Josephine A. Taverna, Seongseok Yun, Jayasree Jonnadula, Ahlam Saleh, Irbaz Bin Riaz, Ivo L Abraham, Andrew M Yeager, Daniel O. Persky, Ali McBride, Subrata Haldar, Faiz - Anwer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Significant uncertainty exists in regard to the efficacy of maintenance therapy after high-dose chemotherapy (HDC) as well as autologous stem cell transplantation (ASCT) for the treatment of patients with aggressive lymphoma. A systematic review was performed to evaluate the effectiveness of post-ASCT maintenance therapy in patients with relapsed/refractory lymphoma. A comprehensive literature search yielded 4476 studies and a total of 42 studies (11 randomized controlled trials [RCT], 9 retrospective comparative studies, and 22 single-arm studies) were included in the systematic review. There was significant heterogeneity in study design, chemotherapeutic regimens, post-ASCT maintenance strategies, patient enrollment criteria, and study endpoints. Our findings suggest that post-ASCT maintenance immune-targeting strategies, including PD-1/PD-L1 blocking antibodies, rituximab, and brentuximab, may improve progression-free survival but not overall survival. Collectively, the results indicate a need for testing new strategies with well-designed and adequately powered RCTs to better address the role of post-ASCT maintenance in relapsed/refractory lymphomas.

Original languageEnglish (US)
Pages (from-to)1182-1196
Number of pages15
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Cell Transplantation
Stem Cell Transplantation
Lymphoma
Drug Therapy
Maintenance
Therapeutics
Blocking Antibodies
Disease-Free Survival
Uncertainty
Randomized Controlled Trials
Retrospective Studies
Survival

Keywords

  • Autologous hematopoietic stem cell transplantation
  • Hodgkin disease
  • Maintenance therapy
  • Non-Hodgkin lymphoma
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas : A Systematic Review. / Taverna, Josephine A.; Yun, Seongseok; Jonnadula, Jayasree; Saleh, Ahlam; Riaz, Irbaz Bin; Abraham, Ivo L; Yeager, Andrew M; Persky, Daniel O.; McBride, Ali; Haldar, Subrata; Anwer, Faiz -.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 7, 01.07.2016, p. 1182-1196.

Research output: Contribution to journalArticle

Taverna, Josephine A. ; Yun, Seongseok ; Jonnadula, Jayasree ; Saleh, Ahlam ; Riaz, Irbaz Bin ; Abraham, Ivo L ; Yeager, Andrew M ; Persky, Daniel O. ; McBride, Ali ; Haldar, Subrata ; Anwer, Faiz -. / Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas : A Systematic Review. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 7. pp. 1182-1196.
@article{5a90b8ee44b44ed7b46c56edad9142e3,
title = "Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review",
abstract = "Significant uncertainty exists in regard to the efficacy of maintenance therapy after high-dose chemotherapy (HDC) as well as autologous stem cell transplantation (ASCT) for the treatment of patients with aggressive lymphoma. A systematic review was performed to evaluate the effectiveness of post-ASCT maintenance therapy in patients with relapsed/refractory lymphoma. A comprehensive literature search yielded 4476 studies and a total of 42 studies (11 randomized controlled trials [RCT], 9 retrospective comparative studies, and 22 single-arm studies) were included in the systematic review. There was significant heterogeneity in study design, chemotherapeutic regimens, post-ASCT maintenance strategies, patient enrollment criteria, and study endpoints. Our findings suggest that post-ASCT maintenance immune-targeting strategies, including PD-1/PD-L1 blocking antibodies, rituximab, and brentuximab, may improve progression-free survival but not overall survival. Collectively, the results indicate a need for testing new strategies with well-designed and adequately powered RCTs to better address the role of post-ASCT maintenance in relapsed/refractory lymphomas.",
keywords = "Autologous hematopoietic stem cell transplantation, Hodgkin disease, Maintenance therapy, Non-Hodgkin lymphoma, Relapse",
author = "Taverna, {Josephine A.} and Seongseok Yun and Jayasree Jonnadula and Ahlam Saleh and Riaz, {Irbaz Bin} and Abraham, {Ivo L} and Yeager, {Andrew M} and Persky, {Daniel O.} and Ali McBride and Subrata Haldar and Anwer, {Faiz -}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2016.02.007",
language = "English (US)",
volume = "22",
pages = "1182--1196",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas

T2 - A Systematic Review

AU - Taverna, Josephine A.

AU - Yun, Seongseok

AU - Jonnadula, Jayasree

AU - Saleh, Ahlam

AU - Riaz, Irbaz Bin

AU - Abraham, Ivo L

AU - Yeager, Andrew M

AU - Persky, Daniel O.

AU - McBride, Ali

AU - Haldar, Subrata

AU - Anwer, Faiz -

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Significant uncertainty exists in regard to the efficacy of maintenance therapy after high-dose chemotherapy (HDC) as well as autologous stem cell transplantation (ASCT) for the treatment of patients with aggressive lymphoma. A systematic review was performed to evaluate the effectiveness of post-ASCT maintenance therapy in patients with relapsed/refractory lymphoma. A comprehensive literature search yielded 4476 studies and a total of 42 studies (11 randomized controlled trials [RCT], 9 retrospective comparative studies, and 22 single-arm studies) were included in the systematic review. There was significant heterogeneity in study design, chemotherapeutic regimens, post-ASCT maintenance strategies, patient enrollment criteria, and study endpoints. Our findings suggest that post-ASCT maintenance immune-targeting strategies, including PD-1/PD-L1 blocking antibodies, rituximab, and brentuximab, may improve progression-free survival but not overall survival. Collectively, the results indicate a need for testing new strategies with well-designed and adequately powered RCTs to better address the role of post-ASCT maintenance in relapsed/refractory lymphomas.

AB - Significant uncertainty exists in regard to the efficacy of maintenance therapy after high-dose chemotherapy (HDC) as well as autologous stem cell transplantation (ASCT) for the treatment of patients with aggressive lymphoma. A systematic review was performed to evaluate the effectiveness of post-ASCT maintenance therapy in patients with relapsed/refractory lymphoma. A comprehensive literature search yielded 4476 studies and a total of 42 studies (11 randomized controlled trials [RCT], 9 retrospective comparative studies, and 22 single-arm studies) were included in the systematic review. There was significant heterogeneity in study design, chemotherapeutic regimens, post-ASCT maintenance strategies, patient enrollment criteria, and study endpoints. Our findings suggest that post-ASCT maintenance immune-targeting strategies, including PD-1/PD-L1 blocking antibodies, rituximab, and brentuximab, may improve progression-free survival but not overall survival. Collectively, the results indicate a need for testing new strategies with well-designed and adequately powered RCTs to better address the role of post-ASCT maintenance in relapsed/refractory lymphomas.

KW - Autologous hematopoietic stem cell transplantation

KW - Hodgkin disease

KW - Maintenance therapy

KW - Non-Hodgkin lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84975317346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975317346&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.02.007

DO - 10.1016/j.bbmt.2016.02.007

M3 - Article

VL - 22

SP - 1182

EP - 1196

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -